BioSpace News Archive

Pulse Biosciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 18,250 shares of Pulse Biosciences common stock to five new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on August 3, 2018.

Neovasc Inc. announced today that it has entered into a collaboration and licensing agreement relating to certain know-how developed by Penn Medicine and the Gorman Cardiovascular Research Group at the University of Pennsylvania (together, “Penn”).

Creative Enzymes, a world leading enzyme products and services provider based in NY, USA, is pleased to provide a variety of enzyme activity assays, including enzyme activity measurement for alcohol dehydrogenases for customers all over the world.

Valens GroWorks Corp. is pleased to announce its AGM and other corporate developments.

IntelGenx Technologies Corp. announced that it will release its second quarter 2018 financial results after market close on Aug 9, 2018.

Corvus Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2018, and provided a business update.

IMPACT Therapeutics, Inc. (IMPACT) today announced the completion of $30 million in series C financing.

Innovus Pharmaceuticals, Inc. announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S. financial markets.

Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet Neurology[1].

Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced the company plans to participate in the 38th Annual Growth Conference hosted by Canaccord Genuity in Boston, MA.